Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US9533973B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9533973-B2 |
| Application number | US-201214363141-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 7, 2012 |
| Priority date | Dec 8, 2011 |
| Publication date | Jan 3, 2017 |
| Grant date | Jan 3, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The disclosure is directed to compounds identified as allosteric modulators of 5-HT 2CR, as well as pharmaceutical compositions and methods using the same. Certain embodiments also include methods of identifying and methods of synthesizing the compounds. Optimization and development of allosteric 5-HT 2CR modulators that bind sites other than the primary ligand binding site generate novel, highly selective, and potent ligands of 5-HT2CR. Such molecules can be used as small molecule probes for the nervous system and as effective therapeutics for a variety of diseases.
Opening claim text (preview).
The invention claimed is: 1. A compound having the general formula of Formula I wherein, Y is —NH; Z is a linear or branched C 1 , C 2 , C 3 , or C 4 , alkyl; R 1 is hydroxy, or hydroxy substituted C 1-4 alkyl; R 2 is hydrogen, hydroxy, or hydroxy substituted C 1-4 alkyl; X is a linear, saturated C 10-15 alkyl; and R 3 is hydrogen, methyl, or ethyl. 2. The compound of claim 1 , wherein R 1 is a hydroxy substituted C 1 alkyl. 3. The compound of claim 1 , wherein R 2 is hydroxy. 4. The compound of claim 1 , wherein the compound is (2,4-cis-4-undecyl-piperidine-2-carboxylic acid (2,3-dihydroxypropyl)amide); or (2,4-cis-4-undecyl-piperidine-2-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)amide).
by oxygen atoms · CPC title
Lincomycin; Derivatives thereof · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Oxygen atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.